BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting
February 09 2023 - 10:09PM
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX:BCT)
(“BriaCell” or the “Company”), a clinical-stage
biotechnology company specializing in targeted immunotherapies for
cancer, is pleased to announce the results of its annual general
and special meeting of shareholders of the Company (the
“
Shareholders”) for the year ended July 31, 2022
held on February 9, 2023 (the “
Meeting”). A total
of 6,663,370 common shares of the Company (the “
Common
Shares”) were voted, representing 42.94% of the Company’s
issued and outstanding Common Shares. At the Meeting, the
Shareholders overwhelmingly voted in favour of all proposed
resolutions that consisted of the following:
-
Appointment of MNP LLP as auditors of the Company for the ensuing
year and authorizing the directors to fix their remuneration;
-
Election of Dr. William V. Williams, Mr. Jamieson Bondarenko, Mr.
Marc Lustig, Dr. Jane A. Gross, Dr. Rebecca Taub, Mr. Vaughn C.
Embro-Pantalony, and Mr. Martin E. Schmieg as directors of the
Company;
-
Approval of the Company’s new omnibus equity incentive plan (the
“Omnibus Plan”);
-
Ratification of restricted share units awarded under the Omnibus
Plan; and
-
Approval and adoption of an amendment to the Articles of the
Company to require the presence, in person or by proxy, of two or
more shareholders representing at least 33 1/3% of the outstanding
shares entitled to be voted in order to constitute a quorum at any
meeting of shareholders, and to remove the quorum exception for
succeeding meetings of shareholders.
Having received Shareholder approval, the
Company’s Omnibus Plan remains subject to final approval from the
Toronto Stock Exchange. The formal report on voting results with
respect to all matters voted upon during the Meeting will be filed
on the Company’s SEDAR profile at www.sedar.com.
About BriaCell Therapeutics
Corp.
BriaCell is an immuno-oncology-focused
biotechnology company developing targeted and effective approaches
for the management of cancer. More information is available at
https://briacell.com/.
Safe Harbor
This press release contains “forward-looking
statements” that are subject to substantial risks and
uncertainties. All statements, other than statements of historical
fact, contained in this press release are forward-looking
statements. Forward-looking statements contained in this press
release may be identified by the use of words such as “anticipate,”
“believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,”
“seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,”
“target,” “aim,” “should,” “will,” “would,” or the negative of
these words or other similar expressions, although not all
forward-looking statements contain these words. Forward-looking
statements are based on BriaCell’s current expectations and are
subject to inherent uncertainties, risks, and assumptions that are
difficult to predict. Further, certain forward-looking statements
are based on assumptions as to future events that may not prove to
be accurate. These and other risks and uncertainties are described
more fully under the heading “Risks and Uncertainties” in the
Company’s most recent Management’s Discussion and Analysis, under
the heading “Risk Factors” in the Company’s most recent Annual
Information Form, and under “Risks and Uncertainties” in the
Company’s other filings with the Canadian securities regulatory
authorities and the U.S. Securities and Exchange Commission, all of
which are available under the Company’s profiles on SEDAR at
www.sedar.com and on EDGAR at
www.sec.gov. Forward-looking statements contained
in this announcement are made as of this date, and BriaCell
Therapeutics Corp. undertakes no duty to update such information
except as required under applicable law.
Neither the Toronto Stock Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the Toronto Stock Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Contact Information
Company Contact:William V. Williams,
MDPresident & CEO1-888-485-6340info@briacell.com
Media Relations:Jules AbrahamDirector of Public
RelationsCORE IR917-885-7378julesa@coreir.com
Investor Relations Contact:CORE
IRinvestors@briacell.com
BriaCell Therapeutics (NASDAQ:BCTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
BriaCell Therapeutics (NASDAQ:BCTX)
Historical Stock Chart
From Jul 2023 to Jul 2024